Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients

Meng, Xiaoxiao; Joosse, Simon A.; Müller, Volkmar; Trillsch, Fabian; Milde‐Langosch, Karin; Mahner, Sven; Geffken, Maria; Pantel, Klaus; Schwarzenbach, Heidi

doi:10.1038/bjc.2015.340

Cited by 106 publications

(94 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The normalized data were statistically evaluated and compared with the clinical parameters of EOC patients. In addition, we selected miR‐200b and miR‐320 for further in vitro and functional analyses because they were significantly deregulated in exosomes from plasma of EOC patients, and their dual character as tumor suppressor genes and oncomiRs with multiple cancer‐specific functions have been described in diverse studies (Li et al ., ; Meng et al ., ; Muralidhar and Barbolina, ; Wang et al ., ). We quantified the levels of these two miRNAs in two cell lines (OVCAR3 and SKOV3) and in exosomes released from these cells.…”

Section: Resultsmentioning

confidence: 99%

“…MiR‐16 may also be a potential therapeutic target and clinical biomarker of bone metastasis, because it is elevated in osteoclast differentiation and bone metastasis (Ell et al ., ). In our present study, we found that lower amounts of miR‐16 were packaged in exosomes from EOC patients, while in our previous study, we detected that the serum levels of circulating miR‐16 were neither up‐ nor downregulated in EOC patients compared with healthy women (Meng et al ., ). Moreover, we observed that the decreased levels of miR‐16 in exosomes from EOC patients further decreased in recurrent patients, suggesting that decrease in levels of exosomal miRNAs is particularly associated with recurrence.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Exosomal microRNAs as tumor markers in epithelial ovarian cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

Specific microRNAs (miRNAs) are packaged in exosomes that regulate processes in tumor development and progression. The current study focuses on the influence of exosomal miRNAs in the pathogenesis of epithelial ovarian cancer (EOC). MiRNA profiles were determined in exosomes from plasma of 106 EOC patients, eight ovarian cystadenoma patients, and 29 healthy women by TaqMan real‐time PCR‐based miRNA array cards containing 48 different miRNAs. In cell culture experiments, the impact of miR‐200b and miR‐320 was determined on proliferation and apoptosis of ovarian cancer cell lines. We report that miR‐21 (P = 0.0001), miR‐100 (P = 0.034), miR‐200b (P = 0.008), and miR‐320 (P = 0.034) are significantly enriched, whereas miR‐16 (P = 0.009), miR‐93 (P = 0.014), miR‐126 (P = 0.012), and miR‐223 (P = 0.029) are underrepresented in exosomes from plasma of EOC patients as compared to those of healthy women. The levels of exosomal miR‐23a (P = 0.009, 0.008) and miR‐92a (P = 009, 0.034) were lower in ovarian cystadenoma patients than in EOC patients and healthy women, respectively. The exosomal levels of miR‐200b correlated with the tumor marker CA125 (P = 0.002) and patient overall survival (P = 0.019). MiR‐200b influenced cell proliferation (P = 0.0001) and apoptosis (P < 0.008). Our findings reveal specific exosomal miRNA patterns in EOC and ovarian cystadenoma patients, which are indicative of a role of these miRNAs in the pathogenesis of EOC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 97%

Exosomal microRNAs as tumor markers in epithelial ovarian cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although the qPCR validation test on miR-93 expression level has been conducted in the previous studies, 57,58,61,62 to our best knowledge, our study is still the first to research miR-93 expression in pan-cancer. In the validation test, the serum miR-93 expression level was detected in 14 cancers and six benign lesion types.…”

Section: Discussionmentioning

confidence: 98%

“…Separately, 11 studies from eight articles 15,[56][57][58][59][60][61][62] were included in the diagnostic meta-analysis and 14 studies from 13 articles 15,24,29,41,47,51,[63][64][65][66][67][68][69] were included in the prognostic meta-analysis. After screening the titles and abstracts, 476 articles were excluded because they were reviews (n = 18), meta-analyses (n = 5), nonhuman studies (n = 14), or studies irrelevant to our topic (n = 439).…”

Section: The Basic Characteristic Of Meta-analysismentioning

confidence: 99%

Molecular mechanism and role of microRNA‐93 in human cancers: A study based on bioinformatics analysis, meta‐analysis, and quantitative polymerase chain reaction validation

Gao

Deng

Liu

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Introduction Currently, studies have shown that microRNA‐93 (miR‐93) can be an oncogene or a tumor suppressor in different kinds of cancers. The role of miR‐93 in human cancers is inconsistent and the underlying mechanism on the aberrant expression of miR‐93 is complicated. Methods We first conducted gene enrichment analysis to give insight into the prospective mechanism of miR‐93. Second, we performed a meta‐analysis to evaluate the clinical value of miR‐93. Finally, a validation test based on quantitative polymerase chain reaction (qPCR) was performed to further investigate the role of miR‐93 in pan‐cancer. Results Gene Ontology (GO) enrichment analysis results showed that the target genes of miR‐93 were closely related to transcription, and MAPK1, RBBP7 and Smad7 became the hub genes. In the diagnostic meta‐analysis, the overall sensitivity, specificity, and area under the curve were 0.76 (0.64‐0.85), 0.82 (0.64‐0.92), and 0.85 (0.82‐0.88), respectively, which suggested that miR‐93 had excellent performance on the diagnosis for human cancers. In the prognostic meta‐analysis, dysregulated miR‐93 was found to be associated with poor OS in cancer patients. In the qPCR validation test, the serum levels of miR‐93 were upregulated in breast cancer, breast hyperplasia, lung cancer, chronic obstructive pulmonary disease, nasopharyngeal cancer, hepatocellular cancer, gastric ulcer, endometrial cancer, esophageal cancer, laryngeal cancer, and prostate cancer compared with healthy controls. Conclusions miR‐93 could act as an effective diagnostic and prognostic factor for cancer patients. Its clinical value for cancer early diagnosis and survival prediction is promising.

show abstract

“…Recently, several studies have reported that some microRNAs were elevated or decreased in the serum of GC patients compared to healthy controls [7,8]. These different expressed microRNAs may be potential biomarkers for GS diagnosis [7,9,10].…”

Section: Introductionmentioning

confidence: 97%

Increased miR-25 expression in serum of gastric cancer patients is correlated with CA19-9 and acts as a potential diagnostic biomarker

et al. 2017

View full text Add to dashboard Cite

AbstractObjectiveTo evaluate miR-25 expression in serum of gastric cancer (GC) patients and whether it can be a potential biomarker for GC diagnosis.MethodsForty one pathology confirmed GC patients and 41 healthy controls were included in this study. 10 mL peripheral venous blood were collected from GC patients and healthy controls. miR-25 relative expression and CA19-9 level in serum of GC patients and healthy controls were measured by real-time reverse transcription quantitative polymerase chain reaction (RT-qPCR) and enzyme linked immunosorbent assay (ELISA), respectively. The diagnostic sensitivity, specificity and receiver operating characteristic (ROC) curve of serum miR-25 and CA19-9 were calculated by STATA11.0 software.ResultsThe relative expression of miR-25 was 0.47±0.53 and 0.05±0.36 in serum of GC patients and healthy controls respectively with significant statistical difference (P<0.05). The serum level of CA19-9 for GC patients and healthy controls were 11.91±6.17 U/mL and 7.40±3.97 U/mL, indicating GC patients were much higher than those of healthy controls (P<0.05). The diagnostic sensitivity and specificity were 78.05% and 60.98% with the cut-off value of 0.32 for serum miR-25. Under this cut-off value, the area under the ROC curve was 0.75. For serum CA19-9, the diagnostic sensitivity and specificity were 70.73% and 56.10% with the cut-off value of 9.22 U/mL. Under this cut-off value, the area under the ROC curve was 0.73 with the 95% confidence interval of 0.62-0.84. Positive correlation was found between serum miR-25 relative expression and CA19-9 concentration of GC patients (r=0.75, P<0.05).ConclusionAccording to our present study, serum miR-25 was elevated in GC patients which may serve as a diagnostic biomarker for GC.

show abstract

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients

Cited by 106 publications

References 42 publications

Exosomal microRNAs as tumor markers in epithelial ovarian cancer

Exosomal microRNAs as tumor markers in epithelial ovarian cancer

Molecular mechanism and role of microRNA‐93 in human cancers: A study based on bioinformatics analysis, meta‐analysis, and quantitative polymerase chain reaction validation

Increased miR-25 expression in serum of gastric cancer patients is correlated with CA19-9 and acts as a potential diagnostic biomarker

Contact Info

Product

Resources

About